Citadel Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-31,900
| Closed | -$687K | – | 12953 |
|
|
2025
Q4 | $687K | Sell |
31,900
-15,800
| -33% | -$307K | ﹤0.01% | 8247 |
|
|
2025
Q3 | $728K | Buy |
+47,700
| New | +$621K | ﹤0.01% | 8248 |
|
|
2025
Q2 | – | Sell |
-9,600
| Closed | -$75.2K | – | 12486 |
|
|
2025
Q1 | $75.2K | Sell |
9,600
-372,100
| -97% | -$3.12M | ﹤0.01% | 11828 |
|
|
2024
Q4 | $4.01M | Buy |
381,700
+3,400
| +0.9% | +$41.3K | ﹤0.01% | 4331 |
|
|
2024
Q3 | $4.96M | Sell |
378,300
-55,200
| -13% | -$841K | ﹤0.01% | 3959 |
|
|
2024
Q2 | $6.1M | Buy |
433,500
+250,600
| +137% | +$4.08M | ﹤0.01% | 3439 |
|
|
2024
Q1 | $3.09M | Buy |
182,900
+31,200
| +21% | +$465K | ﹤0.01% | 4733 |
|
|
2023
Q4 | $2.14M | Sell |
151,700
-153,600
| -50% | -$1.8M | ﹤0.01% | 5234 |
|
|
2023
Q3 | $3.14M | Buy |
305,300
+178,200
| +140% | +$2.39M | ﹤0.01% | 4399 |
|
|
2023
Q2 | $2.09M | Buy |
127,100
+37,500
| +42% | +$487K | ﹤0.01% | 5075 |
|
|
2023
Q1 | $821K | Sell |
89,600
-207,900
| -70% | -$1.71M | ﹤0.01% | 7221 |
|
|
2022
Q4 | $2.13M | Buy |
297,500
+78,400
| +36% | +$550K | ﹤0.01% | 5358 |
|
|
2022
Q3 | $1.1M | Sell |
219,100
-47,200
| -18% | -$260K | ﹤0.01% | 6794 |
|
|
2022
Q2 | $650K | Sell |
266,300
-75,800
| -22% | -$311K | ﹤0.01% | 8060 |
|
|
2022
Q1 | $2.34M | Buy |
342,100
+80,500
| +31% | +$553K | ﹤0.01% | 5747 |
|
|
2021
Q4 | $2.11M | Buy |
261,600
+140,000
| +115% | +$1.28M | ﹤0.01% | 6103 |
|
|
2021
Q3 | $1.19M | Buy |
121,600
+68,500
| +129% | +$539K | ﹤0.01% | 7696 |
|
|
2021
Q2 | $357K | Sell |
53,100
-10,100
| -16% | -$80.2K | ﹤0.01% | 10841 |
|
|
2021
Q1 | $571K | Buy |
63,200
+16,800
| +36% | +$136K | ﹤0.01% | 9391 |
|
|
2020
Q4 | $310K | Sell |
46,400
-81,000
| -64% | -$507K | ﹤0.01% | 9017 |
|
|
2020
Q3 | $642K | Buy |
127,400
+59,700
| +88% | +$434K | ﹤0.01% | 6838 |
|
|
2020
Q2 | $547K | Sell |
67,700
-76,200
| -53% | -$672K | ﹤0.01% | 6918 |
|
|
2020
Q1 | $1.14M | Buy |
143,900
+74,000
| +106% | +$568K | ﹤0.01% | 5091 |
|
|
2019
Q4 | $528K | Buy |
69,900
+57,900
| +483% | +$306K | ﹤0.01% | 6727 |
|
|
2019
Q3 | $50K | Buy |
+12,000
| New | +$30K | ﹤0.01% | 8700 |
|
|
2018
Q4 | – | Sell |
-19,500
| Closed | -$86K | – | 9079 |
|
|
2018
Q3 | $86K | Buy |
19,500
+7,100
| +57% | +$38.3K | ﹤0.01% | 8632 |
|
|
2018
Q2 | $76K | Sell |
12,400
-11,300
| -48% | -$79.3K | ﹤0.01% | 8339 |
|
|
2018
Q1 | $173K | Buy |
+23,700
| New | +$208K | ﹤0.01% | 7447 |
|
Other funds holding AVDL
Citadel Advisors's AVDL Position: Q1 2026 in Review
Citadel Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 770,232 shares — an estimated $16.6M sold.
Citadel Advisors first reported a position in AVDL in Q4 2014 and held it in 39 quarters. The position peaked at $31.5M in Q2 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- Citadel Advisors reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 770,232 Avadel Pharmaceuticals shares in Q1 2026, an estimated $16.6M.
- Citadel Advisors first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 39 quarters.
- Citadel Advisors's Avadel Pharmaceuticals position peaked at $31.5M in Q2 2024.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.